Today Synthace announced the receipt of a highly competitive Technology Strategy Board award, ‘Rapid Engineering of Cellular Factories’, in collaboration with University College London and University of Manchester. Synthetic biology is an emerging, multidisciplinary approach at the intersection of engineering, bioscience, chemistry, and information technology, and builds atop many areas of innovation that the UK has traditionally been world leading in. Fundamentally, it aims to design and engineer novel biologically based parts, devices and systems, and redesign existing natural biological systems for useful purposes.
The Synthace project will integrate several novel technologies as reusable components, including the highly controlled import and export of chemicals from a cell, and the ability to rapidly tune the amount of each part used to assist in the production of a chemical inside of a cell. Together with the other technologies in the Synthace platform, it enables the engineering of a cell which can convert low value feedstocks such as vegetable oils into much higher value chemicals such as pharmaceutical ingredients, fragrances, and pigments. The ability to use more complex feedstocks than simple sugars, and to rapidly tune the parts, reduces the complexity required to develop a cellular factory, and thus the time, cost, and risk associated with such a project. This in turn opens up many more chemical products for bioproduction rather than traditional chemical synthesis, with commensurate advantages in waste production, energy intensity, and in many cases, cost.
Speaking during a visit today to Synthace, Universities and Science Minister David Willetts said:
“Synthetic biology is one of eight key technology areas that I have identified as playing an increasingly important part in the global economy over the coming years. The UK is well positioned in the biological sciences sector and is among the first economies in the world to invest in this exciting area of technology.”
“Companies like Synthace can help the UK exploit the massive potential that synthetic biology has both here and abroad. By making investment in technology now, it will ensure that in ten years time the UK is at the forefront of the global race when it comes to commercialising new technologies.”
The Minister announced grants totalling £5.3 million which were awarded through a competition for business-led, collaborative projects aimed at demonstrating the feasibility of using synthetic biology to create novel or improved products or processes.
Funding came from the Technology Strategy Board, the Biotechnology and Biological Sciences Research Council (BBSRC) and the Engineering and Physical Sciences Research Council (EPSRC). Each of the applications was also assessed according to a series of responsible innovation criteria.
Synthace’s CEO, Sean Ward, commented:
“This funding will enable us to bring together a unique suite of technologies for the rapid engineering of a micro-organism which can produce a commercially high-value chemical. The project will demonstrate a new way of engineering biology, with timescales in months rather than years, which will impact sectors across the UK and global economies.”
UCLB business manager Marina Santilli said:
“Synthace have developed a unique methodology in the synthetic biology sector which is attracting significant attention. The team are pulling together best of breed IP with origins not just in UCL but other leading UK Universities. I’m delighted that Synthace is able to further develop its relationships with the University sector through this collaborative TSB award which brings in UCL and Manchester University as partners and look forward to a successful technology transfer outcome.”
More news on this funding announcement can be found here
Notes to Editors:
Synthace is the UK’s first dedicated synthetic biology company with a world leading platform of technologies for the rapid engineering and optimisation of novel biological production systems. A spin out of University College London, Synthace is already producing high-value research and development products for the pharmaceutical, agrochemical and fine chemicals industry. Synthace bioengineering is enabled by a tight integration of computational modelling and big data analysis with wet lab experimental design and validation, and novel molecular biology tools. While Synthace bioengineering is broadly applicable across multiple industry sectors, the company is focused towards applications in the production of specialty chemicals. More information is available at www.synthace.com
The Technology Strategy Board is the UK’s innovation agency. Its goal is to accelerate economic growth by stimulating and supporting business-led innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org.
The Biotechnology and Biological Sciences Research Council (BBSRC) invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond. Funded by Government, and with an annual budget of around £500M (2012-2013), we support research and training in universities and strategically funded institutes. BBSRC research and the people we fund are helping society to meet major challenges, including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals. For more information about BBSRC, our science and our impact see:http://www.bbsrc.ac.uk For more information about BBSRC strategically funded institutes see: http://www.bbsrc.ac.uk/institutes
The Engineering and Physical Sciences Research Council (EPSRC) is the UK’s main agency for funding research in engineering and the physical sciences. EPSRC invests around £800 million a year in research and postgraduate training, to help the nation handle the next generation of technological change. The areas covered range from information technology to structural engineering, and mathematics to materials science. This research forms the basis for future economic development in the UK and improvements for everyone’s health, lifestyle and culture. EPSRC works alongside other Research Councils with responsibility for other areas of research. The Research Councils work collectively on issues of common concern via Research Councils UK. For more information, visit: www.epsrc.ac.uk
Founded in 1826, UCL was the first English university established after Oxford and Cambridge, the first to admit students regardless of race, class, religion or gender, and the first to provide systematic teaching of law, architecture and medicine. UCL is among the world’s top universities, as reflected by performance in a range of international rankings and tables. UCL currently has 24,000 students from almost 140 countries, and more than 9,500 employees. UCL’s annual income is over £800 million. www.ucl.ac.uk | Follow us on Twitter @uclnews
Established in 1824, The University of Manchester is a member of the Russell Group and is one of is the most popular universities in the UK. Key Facts: Four faculties, 20 academic schools and hundreds of specialist research groups undertaking pioneering multi-disciplinary teaching and research of worldwide significance. Over 5,500 academic and research staff. Over £271 million in external research funding in 2011/12. 25 Nobel Prize winners amongst its current and former staff and students. According to the results of the 2008 Research Assessment Exercise, The University of Manchester is now one of the country’s major research universities, rated third in the UK in terms of ‘research power’. The University had an annual income of £807 million in 2011/12. www.manchester.ac.uk
Enquiries should be addressed to:
CEO, Synthace Limited
Mobile: +447738511117, Email: sward(AT)synthace.com